Walter & Keenan Wealth Management’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Walter & Keenan Wealth Management’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-7,300	Closed	-$252	–	156
2018 Q3	$252	Sell	7,300 -4,000	-35%	-$135K	0.08%	142
2018 Q2	$369K	Buy	11,300 +500	+5%	+$16.4K	0.16%	113
2018 Q1	$1.83M	Buy	+10,800	New	+$352K	0.79%	40

Other funds holding BBC

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AWCI

Alpine Woods Capital Investors Purchase, New York $417M AUM 26.83% 1-Year Est. Return

CCP

Cardan Capital Partners Denver, Colorado $893M AUM 22.82% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Walter & Keenan Wealth Management's BBC Position: Q4 2018 in Review

Walter & Keenan Wealth Management sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q4 2018, closing a stake of 7,300 shares — an estimated $252 sold.

Walter & Keenan Wealth Management first reported a position in BBC in Q1 2018 and held it in 3 quarters. The position peaked at $1.83M in Q1 2018. 17 funds tracked by Wall St. Rank hold BBC as of Q4 2018.

Walter & Keenan Wealth Management reported no remaining Virtus Biotech Clinical Trials ETF position as of Q4 2018 after selling out during the quarter.
Walter & Keenan Wealth Management sold 7,300 Virtus Biotech Clinical Trials ETF shares in Q4 2018, an estimated $252.
Walter & Keenan Wealth Management first reported a position in Virtus Biotech Clinical Trials ETF in Q1 2018 and held it in 3 quarters.
Walter & Keenan Wealth Management's Virtus Biotech Clinical Trials ETF position peaked at $1.83M in Q1 2018.
17 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q4 2018.

Based on Walter & Keenan Wealth Management's 13F filing for Q4 2018, filed 1 Feb 2019.